fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Estradiol 17-b

All products: general benefit

Vagifem 10 · DIN 02325462 · 10 mcg · Vag tablet with Applicator

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Vagifem 10 · DIN 02325462 Manufacturer: Novo Nordisk Canada Inc; listing date 2011-09-15 Health Canada: Marketed since 2010-09-22 · brand VAGIFEM 10 · ATC G03CA03 ESTRADIOL · form Vaginal tablet · route Vaginal · ingredients ESTRADIOL (ESTRADIOL HEMIHYDRATE) 10 MCG · company Novo nordisk canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Vagifem 10: Formulary list price $4.91 per unit (the source does not state the unit; exact figure $4.9061). What the ministry pays, not the patient.

Ministry pays: $4.9061 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02325462)

Source record
DIN 02325462: Vagifem 10 Raw flags: sec3=Y Item: 681600074; group id 734; item number 1801; lccId None; manufacturer id NOO Source form: Vag Tab with Applicator; strength: 10mcg Recorded listing: General benefit Source prices (unrounded): $4.9061; ministry $4.9061 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02325462 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81084
Shortage status: resolved shortage (ended February 18, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02325462
Shortage record checked October 6, 2026

Other products in the same Health Canada class (G03CA): coverage varies; not interchangeable

  • Conjugated estrogens (Premarin): general benefit, limited Use 398
  • Estradiol (Estrace): general benefit, not a benefit
  • Estradiol hemihydrate (Imvexxy): general benefit
Other drugs in the same formulary class (68:16 Estrogens) and how they are covered

Matched class: 68:16 Estrogens

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ESTRADIOL HEMIHYDRATE, ESTRADIOL HEMIHYDRATE & PROGESTERONE Some products covered without a code (check the product listing): CONJUGATED ESTROGENS, ESTRADIOL 68:16 Estrogens

CONJUGATED ESTROGENS

· 2 products · Limited Use, codes 398 (1), General benefit (1) · strengths: 0.625mg, 0.625mg/g · SR Tab, Vag Cr

ESTRADIOL

· 7 products · Listed, not a benefit (3), General benefit (4) · strengths: 0.5mg, 1mg, 2mg · Tab, Vag Ring

ESTRADIOL HEMIHYDRATE

· 2 products · General benefit · strengths: 4mcg, 10mcg · Vag Insert

ESTRADIOL HEMIHYDRATE & PROGESTERONE

· 1 products · General benefit · strengths: 1mg & 100mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 68:16
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:12 Contraceptives, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS Vagifem® 10 (estradiol vaginal insert USP) is indicated for: • The treatment of the symptoms of vaginal atrophy due to estrogen deficiency 1.1 Pediatrics Pediatrics (<18 years of age): Vagifem® 10 is not indicated for use in the pediatric population. https://pdf.hres.ca/dpd_pm/00073342.PDF PM date: not printed or not captured Source product: VAGIFEM 10; DIN 02325462; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.